Pharmacokinetics of C6 Ketone Di-ester

Pharmacokinetics Clinical Trial

Official title:

A Randomized, Parallel Study to Assess the Pharmacokinetics of C6 Ketone Di-ester in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05310058
• Other study ID #: BIO-2201
• Status: Completed
• Phase: N/A
• Start date: April 11, 2022
• Est. completion date: August 23, 2022

Study information

• Verified date: December 2022
• Source: BHB Therapeutics, Ireland LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.

Description:

Recruiting 33 healthy adults to participate in a pharmacokinetic (PK) study of C6 ketone di-ester in a ready to drink beverage matrix. Following randomization, subjects will participate in a full day of PK sample collection prior to being sent home with study product for 1 week. After 1 week of daily consumption, subjects will return to the clinic for a second PK study identical to the first. Blood samples will be collected for 8 hours following test product consumption on both PK days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 23, 2022
• Est. primary completion date: June 8, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject has a BMI 18.5-34.99 kg/m2 (inclusive)

• Subject is willing to consume the study beverage daily starting on Day 0 through Day 7 following taste testing at Visit 1

• Subject is not a smoker and has no plans to change his/her usage of the following products throughout the study period: tobacco, smoking products (including, but not limited to cigarettes, cigars, chewing tobacco, e-cigarettes), and nicotine products (e.g., nicotine gum and/or nicotine patches)

• Subject is a non-user or former user (cessation =3 months) of any marijuana or hemp products and has no plans to use marijuana or hemp products during the study period. No washout is required for topical marijuana or hemp products, but subjects are required to abstain from these products during the study period.

• Subject is willing and able to comply with all study procedures including overnight fasting (12 ± 2 h, water only), maintenance of usual body weight, avoidance of foods or supplements that increase ketone production in the body throughout the entire study period, avoidance of vigorous exercise (moderate habitual exercise is allowed) with the exception of the 24 h prior to Visits 2 and 3 (Days 0 and 7) when subjects must avoid exercise completely

• Subjects is willing to abstain from caffeine during Visits 2 and 3 (Days 0 and 7).

• Subject has a score of 7 to 10 on the Vein Access Scale

• Subject is willing and able to comply with the visit schedule.

• Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history, physical examination findings, and routine laboratory test results.

• Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.

Exclusion Criteria:

• Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages and all other foods/beverages provided in this study, including soy, milk, and peanut.

• Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate)

• Subject has used weight-loss medications (including over-the-counter medications and/or supplements) or participated in weight loss programs

• Unstable use of any prescription medications is not allowed.

• Subject has used ketone supplements (ketone salts or esters, and medium chain triglycerides [MCT]) within 30 days

• Subject has been exposed to any non-registered drug product within 30 days of Visit 1

• Subject has a history or presence of clinically important endocrine (including hyperparathyroidism, type 1 or 2 diabetes mellitus and/or hypoglycemia), cardiovascular (including, but not limited to history of myocardial infarction, peripheral arterial disease, stroke), pulmonary (including uncontrolled asthma), hepatic, renal, gastrointestinal, hematologic, immunologic, dermatologic, rheumatic (including gout), and/or biliary condition(s), that, in the opinion of the Clinical Investigator (has MD qualifications), could interfere with the interpretation of the study results.

• Subject has a history of bariatric surgery for weight reducing purposes

• Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.

• Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1 (Day -7), at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to Visit 2 (Day 0), for subjects with abnormal laboratory test results.

• Subject has any signs or symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days of Visit 2 (Day 0). If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved (at the discretion of the Clinical Investigator) and any treatment (e.g., antibiotic therapy) has been completed at least 5 days prior to testing.

• Subject has experienced any major trauma or any other surgical event within three months

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Dietary Supplement:
• C6 ketone di-ester
C6 ketone di-ester

Locations

Country	Name	City	State
United States	Biofortis	Addison	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
BHB Therapeutics, Ireland LTD	Mérieux NutriSciences Biofortis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve (AUC)	AUC of circulating metabolites in blood	0 - 8 hours
Primary	Cmax	Maximum concentration of circulating metabolites in blood	0 - 8 hours
Primary	Tmax	Time to maximum concentration of circulating metabolites in blood	0 - 8 hours
Primary	Elimination half-life	Time required to reduce metabolite concentration by 50%	0-8 hours